CONCORD BIOTECH LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,492 INR | +4.24% |
|
-0.98% | +1.40% |
| Mar. 18 | Concord Biotech Limited(BSE:543960) added to S&P Global BMI Index | CI |
| Mar. 06 | Concord Biotech's API Plant Gets GMP Certificate from Brazilian Health Regulator | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 9.92B 119M | Sales 2025 * | 12.33B 148M | Capitalization | 150B 1.8B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.01B 36.14M | Net income 2025 * | 3.87B 46.49M | EV / Sales 2024 * | 15 x |
| Net cash position 2024 * | 630M 7.57M | Net cash position 2025 * | 1.64B 19.67M | EV / Sales 2025 * | 12 x |
| P/E ratio 2024 * |
49.6
x | P/E ratio 2025 * |
38.8
x | Employees | 1,180 |
| Yield 2024 * |
0.44% | Yield 2025 * |
0.54% | Free-Float | 21.42% |
More Fundamentals
* Assessed data
More news
| 1 day | +4.24% | ||
| 1 week | -0.98% | ||
| Current month | -10.48% | ||
| 1 month | -5.80% | ||
| 3 months | +5.96% | ||
| 6 months | +21.09% | ||
| Current year | +1.40% |
1 week
1 422.65
1 530.00
1 month
1 422.651 725.00
Current year
1 350.051 725.00
1 year
900.051 725.00
3 years
900.051 725.00
5 years
900.051 725.00
10 years
900.051 725.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ankur Vaid
CEO | Chief Executive Officer | 42 | 09-12-03 |
Sudhir Vaid
CEO | Chief Executive Officer | 71 | 00-05-09 |
Lalit Sethi
DFI | Director of Finance/CFO | 58 | 22-03-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 22-05-23 | |
| Director/Board Member | 79 | 17-01-30 | |
Bharti Khanna
BRD | Director/Board Member | 55 | 17-01-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-18 | 1,492 | +4.24% | 13 723 |
| 24-05-17 | 1,432 | -1.82% | 125,052 |
| 24-05-16 | 1,458 | -1.96% | 41,170 |
| 24-05-15 | 1,487 | -1.06% | 79,241 |
| 24-05-14 | 1,503 | -0.26% | 15,879 |
Delayed Quote NSE India S.E., May 18, 2024 at 03:19 am EDT
More quotes
Concord Biotech Limited is an India-based research and development driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The Company manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic processes and finished formulations. It manufactures fermentation and semi-synthetic based products in the therapeutic segments, such as immunosuppressants, anti-bacterial, oncology, anti-fungal and others. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Vancomycin Hydrochloride, Micafungin Sodium, Mupirocin, Romidepsin, Dactinomycin, and Pravastatin Sodium, among others. It also has a pipeline of API products under development. Its API products under development include Polymyxin B, Fidaxomicin, Doxorubicin, and others. The Company provides products in the critical care, immunology, nephrology, and transplant medicine segments.
Sector
Pharmaceuticals
Calendar
2024-09-03
- Q1 2025 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1,432
INR
Average target price
1,597
INR
Spread / Average Target
+11.53%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +1.40% | 1.8B | |
| -2.32% | 90.45B | |
| +3.68% | 41.45B | |
| -10.90% | 33.57B | |
| -19.56% | 14.73B | |
| -9.06% | 12.82B | |
| -11.34% | 11.7B | |
| -43.53% | 11.44B | |
| +3.75% | 8.79B | |
| -6.32% | 8.35B |
- Stock Market
- Equities
- CONCORDBIO Stock
